Infliximab biosimilar-induced lupus nephritis: A case report.
Mod Rheumatol Case Rep
; 8(1): 74-76, 2023 Dec 29.
Article
in En
| MEDLINE
| ID: mdl-37902434
ABSTRACT
We present a case of microhematuria, proteinuria and hypocomplementemia which developed in a 55-year-old female who was being treated with an infliximab biosimilar for rheumatoid arthritis. Renal biopsy showed lupus nephritis (ISN/RPS classification class IV + V). Treatment with the infliximab biosimilar was discontinued, and treatment with prednisolone, hydroxychloroquine and abatacept was started, resulting in clinical remission of lupus nephritis and RA. Although tumour necrosis factor-α α inhibitors are known to induce production of autoantibodies, symptoms are usually limited to skin involvement or arthritis, and renal complications are rare. Physicians should be aware of the risk of lupus nephritis and carefully monitor patients for the development of renal involvement during treatment with tumour necrosis factor-α inhibitors.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Lupus Nephritis
/
Biosimilar Pharmaceuticals
Limits:
Female
/
Humans
/
Middle aged
Language:
En
Journal:
Mod Rheumatol Case Rep
Year:
2023
Document type:
Article
Affiliation country:
Japan